Research field (2)：
Statistical science
, Pharmacology
Research keywords (6)：
Epidemiology
, Clinical Research
, Meta-analysis
, BIOSTATISTICS
, 臨床試験
, 医薬生物・ゲノム統計解析
Research theme for competitive and other funds (7)：
2021 - 2024 Re-evaluation of evidence reflecting patient's value with individual patient based meta-analysis
2019 - 2022 Development and application of biostatistical methods for longitudinal life course epidemiology data
2015 - 2019 Individual-patient-based data meta-analysis of randomized trials in gastric cancer
2013 - 2017 Association of obesity indexes with metaboric risk factors
2013 - 2017 Re-evaluation of clinical effectiveness of four neuraminidase inhibitors against influenza viruses using molecular biology and epidemiological studies
2009 - 2010 Evaluation of validity of a surrogate variable based on the causal effect
2008 - 2010 Efficient Approaches of Case Registration and Data management in Clinical Trials
Show all
Papers (311)：
Chikako Iwai, Taisuke Jo, Akira Okada, Asahi Fujita, Takaaki Konishi, Koji Oba, Yohei Hashimoto, Hideo Yasunaga. Association between immune checkpoint inhibitors and uveitis in patients with lung cancer, renal cell carcinoma, or malignant melanoma. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2025
Shigenobu Emoto, Kazushige Kawai, Koji Oba, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Yuichiro Yokoyama, Shinya Abe, Kensuke Kaneko, Yuzo Nagai, et al. Preoperative chemoradiotherapy with the TEGAFIRI regimen achieves significant local control in locally advanced rectal cancer. International journal of colorectal disease. 2025. 40. 1. 76-76
Hirohiko Motoki, Izuru Masuda, Koji Oba, Shinji Yasuno, Yoshito Inobe, Nobuyuki Azuma, Masako Waki, Takeshi Kimura, Wataru Shoin, Koji Yoshie, et al. Investigation of the Effect of Empagliflozin on Cardiac Sympathetic and Parasympathetic Nerve Activity Analyzed From Heart Rate Variability Frequency in Japanese Patients With Type 2 Diabetes - Results From the EMPYREAN Study. Circulation journal : official journal of the Japanese Circulation Society. 2025
Akiko Sankoda, Yugo Nagae, Kayo Waki, Wei Thing Sze, Koji Oba, Makiko Mieno, Masaomi Nangaku, Toshimasa Yamauchi, Kazuhiko Ohe. Correction: Glycemic Control, Renal Progression, and Use of Telemedicine Phone Consultations Among Japanese Patients With Type 2 Diabetes Mellitus During the COVID-19 Pandemic: Retrospective Cohort Study. JMIR diabetes. 2025. 10. e72076
Yuta Norimatsu, Takemichi Fukasawa, Yuki Ohno, Yurie Norimatsu, Kazuki M Matsuda, Teruyoshi Hisamoto, Hirohito Kotani, Ai Kuzumi, Asako Yoshizaki-Ogawa, Takuya Miyagawa, et al. Validation of Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score and establishment of novel score in Japanese patients with necrotizing fasciitis (J-LRINEC score). The Journal of dermatology. 2025. 52. 3. 439-444
Larbi Aluariachy, Isao Yokota, Kentaro Sakamaki, Koji Oba. Dynamic Prediction of Survival Outcomes Using Longitudinal Biomarkers. Japanese Journal of Biometrics. 2024. 45. 2. 189-214
Multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BITS study).
(JOURNAL OF CLINICAL ONCOLOGY 2019)
Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
(ARTHRITIS & RHEUMATOLOGY 2018)
SAPPHIRE: A randomized phase II study of mFOLFOX6+panitumumab versus 5-FU/LV + panitumumab after 6 cycles of frontline mFOLFOX6+panitumumab in patients with colorectal cancer.
(JOURNAL OF CLINICAL ONCOLOGY 2018)
Trial in progress: A phase II study of second-line FOLFIRI plus panitumumab after first-line FOLFOX plus panitumumab for RAS wild-type colorectal cancer with evaluation of circulating tumor DNA.
(JOURNAL OF CLINICAL ONCOLOGY 2018)
Clinical impact of postoperative surgical complications on the colorectal cancer survival and recurrence: Analyses of pooled individual patients' data from three large phase III randomized trials
(ANNALS OF ONCOLOGY 2017)
